Splenic Rupture in a COVID-19 Patient – A Case Report

Anna C. Crowley,¹ Raul R. Magadia,² Arianna B. Lanpher,³

Abstract

Background: It is well known that the Coronavirus disease 2019 (COVID-19) causes coagulation changes, requiring frequent monitoring for potential sequelae such as myocardial infarction and stroke. Non-traumatic splenic rupture is a rare and poorly understood occurrence in the clinical setting. Possible causes of nontraumatic splenic rupture include neoplasm, infection, inflammatory disease, iatrogenic and mechanical causes. Furthermore, increased intrasplenic tension, increased abdominal pressure, and thomboembolic vascular occlusion are possible mechanisms. The Case: We report a case of splenic rupture in a COVID-19 patient. Our patient was a 52-year-old black man, presenting with diarrhea and moderate dyspnea, who was found to be COVID-19 positive. He had a past medical history significant for end-stage renal disease, chronic anemia, and aortic valve replacement. In an otherwise uneventful, 7-day hospital course, the patient’s stay abruptly resulted in a nontraumatic splenic rupture and demise. In this report, we have evaluated the likelihood of COVID-19 causing splenic rupture in a patient with no prior splenic disease. Conclusion: This case highlights the possibility of splenic rupture in otherwise normally recovering COVID-19 patients, particularly in the presence of comorbid conditions of renal failure and anticoagulation, with increased abdominal pressure during routine defecation. This information may assist in furthering the pathophysiology of COVID-19 and its life-threatening complications. In patients with COVID-19, non-traumatic splenic rupture should be considered as one of the differential diagnoses in patients who present with abdominal pain and early recognition of the same, owing to a high index of suspicion, can be lifesaving.

Key Words: Case report; COVID-19; Splenic rupture (Source: MeSH-NLM).

Introduction

While the Coronavirus disease 2019 (COVID-19) is known to present with significant pulmonary and cardiac manifestations, other systemic complications and interactions with pre-existing pathology are being recognized.¹ As the pandemic has evolved, hypercoagulability and microvascular changes are becoming more prevalent causes of mortality.² Here, we describe a case of nontraumatic splenic rupture in a COVID-19 patient being treated with anticoagulants and routine hemodialysis. Atraumatic splenic rupture is exceedingly rare and a potentially fatal condition. Causes of atraumatic splenic rupture include neoplasms, infection, iatrogenic, mechanical and inflammatory states.³ This case illustrates how interactions with chronic renal disease and anticoagulation use may be important considerations in the treatment of complicated COVID-19 patients.

The Case

History of Present Illness
A 52-year-old Black male presented to the Emergency Department with a chief complaint of diarrhea for 1 day, followed by moderate dyspnea. At the time of admission, the BUN/Cr ratio was 44/11.3, and on admission, the SARS-CoV-2 antigen by IFA (in-house, Sofia) was positive. The patient was afebrile (36.9 °C), and the oxygen saturation was 100% on room air.

Past Medical History
He had a past medical history of hypertension, hepatitis B (2006), end-stage renal disease (2005), hyperlipidemia, severe anemia (2008), and aortic valve replacement (2019). Current medications included warfarin (10mg daily, in addition to supplemental 5mg on M/W/F) due to past mechanical aortic valve replacement. The patient’s goal INR was 2.5-3.5. The patient had a history of hemodialysis noncompliance and often did not attend the recommended treatments. From laboratory data in 2019, the patient’s average BUN/Cr was 34.2/6.5, respectively. Patient denied any recent travel. He did not have any personal or family history of leukemia, lymphoma, coagulopathies, DVT/PE, auto-immune pathology, or other neoplasms.

Investigations
Laboratory results on admission were significant for pancytopenia, anemia, platelet count of 160.7 (10⁹/L), and an average Hgb/Hct of 8.2/25.6 (g/dL/%), respectively. Physical exam revealed normal lung sounds, no hepatosplenomegaly, or lymphadenopathy. Prior to this admission, the patient was evaluated for further renal disease progression in December 2018. There was no evidence of splenic injury or splenomegaly on the 2018 abdominal CT.

Highlights:
- Presentation of a unique case of COVID-19 complicated by non-traumatic splenic rupture.
- Diagnostic dilemma of conflicting coagulation studies in a COVID-19 patient with chronic renal failure requiring hemodialysis and valve replacement requiring warfarin therapy, leading to splenic rupture, a complication that is associated with hypocoagulable state.
- Highlights possibility of fatal splenic rupture in COVID-19 patients with comorbid renal disease and complex coagulation states, reminding clinicians that rapid diagnosis and surgical correction can be lifesaving.

Case Report

The Case

Backround: It is well known that the Coronavirus disease 2019 (COVID-19) causes coagulation changes, requiring frequent monitoring for potential sequelae such as myocardial infarction and stroke. Non-traumatic splenic rupture is a rare and poorly understood occurrence in the clinical setting. Possible causes of nontraumatic splenic rupture include neoplasm, infection, inflammatory disease, iatrogenic and mechanical causes. Furthermore, increased intrasplenic tension, increased abdominal pressure, and thomboembolic vascular occlusion are possible mechanisms. The Case: We report a case of splenic rupture in a COVID-19 patient. Our patient was a 52-year-old black man, presenting with diarrhea and moderate dyspnea, who was found to be COVID-19 positive. He had a past medical history significant for end-stage renal disease, chronic anemia, and aortic valve replacement. In an otherwise uneventful, 7-day hospital course, the patient’s stay abruptly resulted in a nontraumatic splenic rupture and demise. In this report, we have evaluated the likelihood of COVID-19 causing splenic rupture in a patient with no prior splenic disease. Conclusion: This case highlights the possibility of splenic rupture in otherwise normally recovering COVID-19 patients, particularly in the presence of comorbid conditions of renal failure and anticoagulation, with increased abdominal pressure during routine defecation. This information may assist in furthering the pathophysiology of COVID-19 and its life-threatening complications. In patients with COVID-19, non-traumatic splenic rupture should be considered as one of the differential diagnoses in patients who present with abdominal pain and early recognition of the same, owing to a high index of suspicion, can be lifesaving.

Key Words: Case report; COVID-19; Splenic rupture (Source: MeSH-NLM).

Introduction

While the Coronavirus disease 2019 (COVID-19) is known to present with significant pulmonary and cardiac manifestations, other systemic complications and interactions with pre-existing pathology are being recognized.¹ As the pandemic has evolved, hypercoagulability and microvascular changes are becoming more prevalent causes of mortality.² Here, we describe a case of nontraumatic splenic rupture in a COVID-19 patient being treated with anticoagulants and routine hemodialysis. Atraumatic splenic rupture is exceedingly rare and a potentially fatal condition. Causes of atraumatic splenic rupture include neoplasms, infection, iatrogenic, mechanical and inflammatory states.³ This case illustrates how interactions with chronic renal disease and anticoagulation use may be important considerations in the treatment of complicated COVID-19 patients.

The Case

History of Present Illness
A 52-year-old Black male presented to the Emergency Department with a chief complaint of diarrhea for 1 day, followed by moderate dyspnea. At the time of admission, the BUN/Cr ratio was 44/11.3, and on admission, the SARS-CoV-2 antigen by IFA (in-house, Sofia) was positive. The patient was afebrile (36.9 °C), and the oxygen saturation was 100% on room air.

Past Medical History
He had a past medical history of hypertension, hepatitis B (2006), end-stage renal disease (2005), hyperlipidemia, severe anemia (2008), and aortic valve replacement (2019). Current medications included warfarin (10mg daily, in addition to supplemental 5mg on M/W/F) due to past mechanical aortic valve replacement. The patient’s goal INR was 2.5-3.5. The patient had a history of hemodialysis noncompliance and often did not attend the recommended treatments. From laboratory data in 2019, the patient’s average BUN/Cr was 34.2/6.5, respectively. Patient denied any recent travel. He did not have any personal or family history of leukemia, lymphoma, coagulopathies, DVT/PE, auto-immune pathology, or other neoplasms.

Investigations
Laboratory results on admission were significant for pancytopenia, anemia, platelet count of 160.7 (10⁹/L), and an average Hgb/Hct of 8.2/25.6 (g/dL/%), respectively. Physical exam revealed normal lung sounds, no hepatosplenomegaly, or lymphadenopathy. Prior to this admission, the patient was evaluated for further renal disease progression in December 2018. There was no evidence of splenic injury or splenomegaly on the 2018 abdominal CT. The patient’s pancytopenia...
was evaluated during his stay at the hospital; both nutritional and viral etiologies, as well as bone marrow failure, were ruled out with appropriate investigations, as shown in Table 1. Peripheral smear was unremarkable.

Hospital Course: On the second day of admission, the patient received dialysis, and over the next six days underwent a total of three hemodialysis treatments coupled with three separate packed RBC transfusions because of his severe anemia. His chest radiograph remained clear and diarrhea subsided by Day 2. Due to the belief that the patient’s symptoms were due to COVID-19 initially, no abdominal imaging was performed on admission. On Day 5, the INR increased to 5.13 and remained above the therapeutic range (2.5-3.5) for the remainder of his hospital course. After the patient’s increase in coagulation studies, his regular warfarin treatment regimen (10 mg daily, in addition to supplemental 5 mg on M/W/F) was discontinued on day 6.

On Day 8, when attempting defecation, the patient felt a “pop” and developed tearing and burning LLQ flank pain at 8:00. This bowel movement was blood-tined and loose. His abdominal pain progressed throughout the day, and at 16:00, the internist’s physical examination revealed a firm abdomen with no rebound tenderness. CT scan of the abdomen was compatible with acute splenic hemorrhage. Before emergency splenectomy could be performed, the patient became hypotensive, developed cardiac arrest at 18:55, and expired at 19:12.

The abdominal CT detected a large amount of heterogenous material surrounding the spleen with small to moderate amount of free fluid around the spleen, compatible with acute splenic hemorrhage, as shown in Figure 1. Due to the abrupt onset of acute intra-abdominal hemorrhage, the patient died prior to splenectomy or other life-saving interventions. No autopsy was performed.

Figure 1. Abdominal CT confirming splenic rupture

Legend: Impression Per Radiology: 1. Large amount of heterogenous material surrounding the spleen with small to moderate amount of free fluid in the abdomen compatible with acute splenic hemorrhage. 2. Renal findings compatible with autosomal dominant polycystic kidney disease. 3. Small bilateral pleural effusions, greater on the left. 4. Atherosclerosis

Throughout the patient’s stay, he received the standard in-house COVID-19 treatment, including five days of Ascorbic acid (50 mL 2000mg/4 mL IV), Thiamine HCl (2ml 200 mg/2 mL IV), and Zinc Sulfate (20 mg oral QD), along with his continued warfarin anticoagulation as previously prescribed until its discontinuation on Day 6.

Discussion

We believe this case of non-traumatic splenic rupture in a COVID-19 patient was caused by interactions from COVID-19-related coagulation changes. Based on recent data, COVID-19 has been shown to cause both hypercoagulable and hyperfibrinolytic states in patients. Because our patient was on chronic warfarin therapy and reached supratherapeutic levels during hospital days 5-8, we believe the effects of COVID-19 affected our patient’s coagulability and possibly led to his hemorrhagic state and splenic rupture.

While the exact etiology of nontraumatic splenic rupture is not fully understood, three possible mechanisms could explain this patient’s unfortunate clinical course: increased intrasplenic tension, increased abdominal pressure, and altered coagulation. We believe the supratherapeutic warfarin levels and hyperfibrinolytic state caused by COVID-19 led to our patient’s altered coagulation studies. The process of defecation is a known inciting event for splenic rupture due to the rising intrabdominal pressure and stretching of the splenocolic ligament causing rupture of pre-existing subcapsular hematoma. While the inciting event in our patient was caused by interactions from COVID-19-related coagulation studies, our patient was on chronic warfarin therapy and reached supratherapeutic levels during hospital days 5-8, we believe the effects of COVID-19 led to our patient’s altered coagulation studies. The process of defecation is a known inciting event for splenic rupture due to the rising intrabdominal pressure and stretching of the splenocolic ligament causing rupture of pre-existing subcapsular hematoma.

It is relevant to eliminate the other causes of nontraumatic splenic rupture. Because our patient did not receive an autopsy following his death, we cannot be certain that our patient did not have an underlying hematologic disease, splenomegaly, neoplasm). Therefore, we believe COVID-19 infection was a contributing cause of splenic rupture in our patient.

There have been other recently reported cases of nontraumatic splenic rupture in the setting of COVID-19. Research demonstrates that COVID-19 has a direct effect on the body’s secondary lymph tissue. Following these studies, there is further reason to suspect the virus has the potential to have a direct effect on the spleen by causing “lymphoid follicle attrition and nodular atrophy in addition to microvascular thrombosis and necrosis,” as stated in a case report by Shaukat and colleagues.

In monitoring COVID-19 progression, clinicians monitor inflammatory markers, such as C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, and lymphocytes. As shown in Table 1, several other laboratory values are now closely monitored to evaluate the coagulation changes related to the COVID-19 pathogenesis including d-dimer, fibrinogen, prothrombin time, partial thromboplastin time, platelet count, and other specific quantifications such as calcium. Although the mechanism is still unknown, elevated coagulation markers support studies documenting many critically ill COVID-19 patients who suffer from a thrombotic microvascular event. Studies have suggested that in the setting of COVID-19, symptoms such as abdominal pain may be an indication for abdominal CT scan on admission and frequent monitoring throughout the patient’s disease progression. In a reported case of splenic rupture in Poursina Hospital in Rasht, Iran, a COVID-19-related hemorrhage of the spleen was identified in a patient with a history of chronic warfarin therapy and severe COVID-19 infection.
Splenic Rupture in a COVID-19 Patient – Case Report

Crowley AC, et al.

Table 1. Inpatient laboratory values.

<table>
<thead>
<tr>
<th>Test</th>
<th>Ref. Range</th>
<th>Day 0</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>D6</th>
<th>D7</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (10³/μL)</td>
<td>4.5-10.4</td>
<td>1.5</td>
<td>1.6</td>
<td>1.7</td>
<td>1.8</td>
<td>2.8</td>
<td>3.5</td>
<td>5.2</td>
<td>5.4</td>
</tr>
<tr>
<td>RBC (10¹²/μL)</td>
<td>3.7-5.3</td>
<td>2.41</td>
<td>2.37</td>
<td>2.11</td>
<td>2.29</td>
<td>2.10</td>
<td>3.64</td>
<td>2.04</td>
<td>1.91</td>
</tr>
<tr>
<td>Hgb(g/dL)/Hct (%)</td>
<td>11.0-16.0/35-47.0</td>
<td>7.8-13.5</td>
<td>7.4-22.9</td>
<td>6.6-20.8</td>
<td>6.9-22.2</td>
<td>6.5-20.4</td>
<td>5.2-16.5</td>
<td>6.5-19.9</td>
<td>6.0-18.2</td>
</tr>
<tr>
<td>Platelet (10³/μL)</td>
<td>140-440</td>
<td>54</td>
<td>62</td>
<td>60</td>
<td>59</td>
<td>76</td>
<td>68</td>
<td>72</td>
<td>69</td>
</tr>
<tr>
<td>INR</td>
<td></td>
<td>2.93</td>
<td>--</td>
<td>2.24</td>
<td>2.22</td>
<td>2.84</td>
<td>5.13</td>
<td>4.65</td>
<td>4.73</td>
</tr>
<tr>
<td>PT (s)</td>
<td>9.8-11.6</td>
<td>29.8</td>
<td>--</td>
<td>23.1</td>
<td>22.9</td>
<td>28.9</td>
<td>50.8</td>
<td>46.2</td>
<td>47</td>
</tr>
<tr>
<td>aPTT (s)</td>
<td>23.1-31.6</td>
<td>56.6</td>
<td>--</td>
<td>56.6</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>AST (unit/L)</td>
<td>0.2-2.5</td>
<td>2.33</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>ALT (unit/L)</td>
<td>13-61</td>
<td>12</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Albumin (gm/dL)</td>
<td>3.4-5</td>
<td>2.7</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>8.0-252.0</td>
<td>2184.5</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>0.0-3.0</td>
<td>24.5</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Procalcitonin (ng/mL)</td>
<td>&lt;0.10</td>
<td>0.52</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Sed Rate (mm/h)</td>
<td>0-30</td>
<td>53</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>D-dimer</td>
<td>0.19-0.5</td>
<td>2.92</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>LDH (unit/L)</td>
<td>53-241</td>
<td>360</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>BUN/Cr</td>
<td>7-18/6.6-11.3</td>
<td>44/11.3</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Lymphocyte (%)</td>
<td></td>
<td>25.5</td>
<td>43.0</td>
<td>36.5</td>
<td>32.6</td>
<td>27.3</td>
<td>25.1</td>
<td>22.9</td>
<td>16.5</td>
</tr>
<tr>
<td>Monocyte (%)</td>
<td></td>
<td>9.4</td>
<td>13.3</td>
<td>17.1</td>
<td>11.4</td>
<td>9.1</td>
<td>13.6</td>
<td>12.9</td>
<td>11.9</td>
</tr>
</tbody>
</table>

Patient had vague abdominal symptoms and subsequent signs of decompression. Urgent laparotomy was performed, revealed atraumatic splenic rupture, and splenectomy was performed. Fortunately, the acuity of these physicians’ actions were able to save the patient’s life.11

Due to the multisystem involvement of COVID-19, coagulation studies are becoming increasingly relevant in that the virus can cause both hypercoagulable and hemorrhagic changes. We are assuming that our patient’s hyperfibrinolytic state led to his splenic hemorrhage. While the coronavirus remains a heavily studied topic both microbiologically and clinically, it is pertinent that clinicians grow more cognizant of emerging complications related to COVID-19. This case highlights the importance of monitoring coagulation studies while maintaining a high index of suspicion for rare but life-threatening intra-abdominal complications. In patients with COVID-19, non-traumatic splenic rupture should be considered as one of the differential diagnoses in patients who present with abdominal pain and early recognition of the same, owing to a high index of suspicion, can be lifesaving.

References

Acknowledgments
None

Conflict of Interest Statement & Funding
The Authors have no funding, financial relationships or conflicts of interest to disclose.

Author Contributions
Conceptualization: CAC, RRM, ABL. Visualization: CAC, ABL. Data Curation, Investigation, Project Administration, Writing – Original Draft Preparation: CAC. Supervision, Validation: RRM, Writing – Review and Editing: RRM, ABL.

Cite as

This work is licensed under a Creative Commons Attribution 4.0 International License

ISSN 2076-6327
This journal is published by the University Library System, University of Pittsburgh as part of the Digital Publishing Program and is co-sponsored by the University of Pittsburgh Press.